A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options.

Wall Street was moving higher still shortly after the open, on the back of slightly better-than-expected readings for US ...

Walmart’s latest brand and logo update has left some social media ... In a statement, William White, senior vice president and chief marketing officer, Walmart U.S, said, in part, “This ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...

In a court filing on Monday, the Department of Health and Human Services fired back at Vertex Pharmaceuticals, standing by a directive that the biotech’s proposed fertility services program to go with ...

Vertex Pharmaceuticals (VRTX) comes in second with a score of 4.04 and a Buy rating given its dominance in the cystic fibrosis treatment category and diversified pipeline, making a compelling case ...

NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Monday,RTT News reports.